SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as investors speculate about a potential buyout amid strong volume, while the community remains divided over management's leadership and the stock's significant undervaluation relative to its revenue. Discussions are heavily focused on the company's long-term potential in rare disease genetic therapies versus its ongoing struggle to break out of a persistent downtrend.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is experiencing significant volatility and social media attention following the announcement of a new distribution deal with NBCUniversal and the start of the FIFA World Cup, both viewed by the community as key catalysts for growth. Investors are actively debating the stock's potential for a short squeeze due to high short interest and limited float, while many remain focused on whether these developments can restore long-term value against a backdrop of past management challenges and subscriber churn concerns.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors react to management’s renewed focus on a potential eBay acquisition and the CEO’s decision to waive his performance pay package. The community remains deeply divided, with bulls pointing to improved EBITDA guidance as evidence of a structural turnaround, while skeptics express frustration over years of sideways price action and ongoing debates regarding dilution and short interest.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors speculate on potential inclusion in the Russell 1000 index, driving significant options activity and ongoing conflict between bullish sentiment and short sellers. While community members debate the probability of index graduation, the high volume and anticipation of upcoming company announcements have fueled increased buying pressure and social media discourse.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing intense community focus surrounding its upcoming annual shareholder meeting and the strategic expansion of its manufacturing capacity, which many investors view as a critical inflection point for transitioning from R&D to commercial shipments. While the stock has faced downward pressure, bulls remain optimistic that the company's recent paid development agreements with high-power customers and a massive production ramp-up target provide a strong foundation for future revenue growth, especially as investors closely monitor developments regarding the company's U.S. redomiciliation.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending as investors react to a positive FDA assessment of its mRNA-1010 flu vaccine ahead of a pivotal advisory committee vote. The community is actively debating the company's long-term potential in the oncology and rare disease markets, while closely monitoring organizational shifts and potential policy changes regarding vaccine funding.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digital is trending as investors aggressively rotate capital into memory and storage leaders, driven by sticky demand in AI data centers and ongoing supply-side constraints. The community remains heavily focused on potential supply chain bottlenecks and the cyclical versus structural nature of the current memory rally, leading to high-volume price swings and intense debate over the sustainability of recent gains.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently seeing significant volatility driven by a combination of index rebalancing, market-wide rotation, and speculative trading around its role in powering AI data centers. While some market participants are taking profits following an extended run, others remain bullish on the long-term potential for its fuel cell technology to solve critical energy bottlenecks for hyperscalers.

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

AtaiBeckley Inc.

Atai is currently navigating market volatility following its recent Russell index inclusion and the sector-wide optimism surrounding regulatory fast-tracking for psychedelic therapies. While the community remains focused on the potential for a major partnership or acquisition deal, some investors are expressing frustration over the stock's inability to hold gains after price spikes.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors react to robust Phase 3 clinical data for retatrutide and ongoing momentum in its Foundayo weight-loss franchise, reinforcing its lead in the GLP-1 sector. The community is actively discussing the stock's role as a resilient defensive play within the broader healthcare sector, alongside significant speculation regarding its aggressive M&A strategy to expand its pipeline beyond metabolic treatments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LivaNova to Announce Second-Quarter 2026 Results

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2026 results on Wed., Aug. 5, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its second-quarter 2026 results prior to the call...

LivaNova Reports Improved OSA Outcomes With PolySync Programming

LIVN's PolySync data show an 84.5% AHI response rate in OSA patients, building on OSPREY results for its aura6000 System.

LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced new data showing that use of its PolySync programming algorithm increased the cumulative apnea-hypopnea index (AHI) response rate to 84.5% in patients with moderate to severe Obstructive Sleep Apnea (OSA) when...

Jette Nygaard-Andersen Joins LivaNova Board as a New Director

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced the election of Jette Nygaard-Andersen to the Companys Board of Directors after its Annual General Meeting of shareholders on June 10. Were pleased to welcome Jette to LivaNovas Board, said William Kozy, Chair. She...

LivaNova Appoints Anne Liddy as Chief Legal Officer

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the appointment of Anne Liddy as Chief Legal Officer, effective August 31. Liddy will oversee the Companys global legal and compliance function and serve as a member of the Executive Leadership Team. Liddy...

Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift?

NeuroPace exits DIXI, doubles down on RNS as Q1 narrows losses and lifts 2026 guidance, Medicare and pricing actions support margins.

NPCE Explains How NeuroPace's RNS System Makes Money

NeuroPace tightens focus on its RNS epilepsy implant, exits DIXI distribution and pushes AI + cloud workflow tools as 2026 revenue guidance rises.

NeuroPace NPCE and the Next Wave of AI-Driven Epilepsy Care

NPCE bets on AI ECoG Assistant and cloud upgrades as it refocuses on RNS, while IGE label review and coverage timing loom.

LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Stefano Folli will join the Company as incoming President, Cardiopulmonary (CP), effective June 1, succeeding Franco Poletti, who will retire on July 31. Folli will partner closely with Poletti over the...

LivaNova to Present at Goldman Sachs Global Healthcare Conference in June

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, Fla. Vladimir...

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the following segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support (ACS). The Cardiopulmonary segment is involved in the design, development, manufacture, marketing and selling of cardiopulmonary products. The Neuromodulation segment is associated in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating DRE and DTD. The ACS segment deals with the design, development, manufacture, marketing and selling of temporary life support products. The company was founded in 1987 and is headquartered in London, the United Kingdom.

LivaNova PLC

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

LIVNLivaNova PLC

Latest LIVN News